Key terms
About DCGO
DocGo, Inc. engages in the provision of mobile health services. It operates through the following segments: Transportation Services, Mobile Health Solutions, and Corporate. The Transportation Services segment offers on-demand medical mobility solutions which are marketed under the Ambulnz brand. The Mobile Health Solutions segment includes on-site evaluations, diagnostics, triage, treatment, and medicine administration. The Corporate segment consists of information technology expenses. The company was founded in 2015 by Stanley Vashovsky and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DCGO news
Yesterday
9:05am ET
DocGo (DCGO) Has a New Rating from Northland Securities
Yesterday
9:01am ET
DocGo price target lowered to $5 from $8.20 at Deutsche Bank
Yesterday
8:40am ET
DocGo price target lowered to $7 from $10 at Needham
Yesterday
7:36am ET
DocGo price target lowered to $5 from $11 at Cantor Fitzgerald
Yesterday
7:20am ET
DocGo price target lowered to $7 from $11 at BTIG
Yesterday
7:10am ET
Analysts Are Bullish on Top Healthcare Stocks: DocGo (DCGO), Avadel Pharmaceuticals (AVDL)
Yesterday
6:58am ET
DocGo price target lowered to $5 from $9 at Canaccord
Yesterday
6:58am ET
Buy Rating on DocGo: Strong Growth Potential and Financial Health Despite Revenue Base Changes
May 08
4:39pm ET
DocGo cuts FY24 revenue guidance to $600M-$650M from $720M-$750M
Apr 30
7:20am ET
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), DocGo (DCGO) and Revvity (RVTY)
Apr 30
7:16am ET
DocGo price target lowered to $6.50 from $8 at Stifel
Apr 11
7:12am ET
DocGo price target lowered to $9 from $10 at Canaccord
Apr 10
2:15pm ET
DocGo signs extension, starts transition of asylum seeker contract with NYC HPD
Mar 20
7:41am ET
DocGo CFO bought 10,000 shares at $3.61 per share on March 14
Mar 08
7:22am ET
DocGo Announces Leadership Shuffle and New Board Chair
Mar 01
12:15am ET
3 Best Stocks to Buy Now, 3/1/2024, According to Top Analysts
Feb 29
8:35am ET
Northland Securities Sticks to Their Buy Rating for DocGo (DCGO)
Feb 29
8:18am ET
Stifel Nicolaus Remains a Buy on DocGo (DCGO)
Feb 29
7:38am ET
DocGo price target lowered to $10 from $11 at Canaccord
Feb 29
6:52am ET
Buy Rating Affirmed for DocGo: Strong FY23 Finish and Promising FY24 Outlook Fuel Growth Prospects
Feb 29
6:40am ET
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)
Feb 28
4:12pm ET
DocGo sees FY24 revenue $720M-$750M, consensus $753.94M
Feb 28
4:12pm ET
DocGo reports Q4 EPS 6c, consensus 10c
Feb 23
7:55am ET
DocGo price target lowered to $11 from $12 at Stifel
Feb 23
7:22am ET
Stifel Nicolaus Remains a Buy on DocGo (DCGO)
Apr 16
11:30pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against DocGo Inc. and Encourages Investors with Losses to Contact the Firm
Apr 15
3:00am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against DocGo Inc. and Encourages Investors with Losses to Contact the Firm
Apr 11
8:58am ET
Attention Long-Term DocGo Inc. (DCGO) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf
Apr 08
7:00pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against DocGo Inc. and Encourages Investors with Losses to Contact the Firm
Mar 26
9:33am ET
Attention Long-Term DocGo Inc. (DCGO) Investors
Mar 20
12:44pm ET
DocGo Inc. (DCGO) Investor Alert: Grabar Law Office Investigates Claims on Behalf Of DocGo Investors
DCGO Financials
Key terms
Ad Feedback
DCGO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DCGO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
